ReviewFrontiers in immunology2026
Programmed cell death mechanisms of traditional plant medicine in prostate cancer therapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) is a prevalent malignancy in males with high morbidity and mortality. Although treatment modalities have evolved considerably, tumor resistance, recurrence, and metastasis persist, urgently requiring the exploration of alternative therapies for PCa. There is ongoing research on finding and identifying the use of traditional plant medicine (TPM). Cellular homeostasis comprises a sophisticated network of metabolic processes that functions cooperatively to preserve a stable intracellular environment. Programmed cell death (PCD) plays an important role in PCa mechanism. Thus, they represent an effective strategy for targeting PCa. TPM has been proven to induce PCD through multiple pathways and target in the treatment of PCa. Recent reviews have only focused on the one of the PCD, and autophagy, apoptosis, pyroptosis, ferroptosis, and necroptosis are not simultaneously reviewed. Methods: The search strategy: articles with the title containing "prostate cancer", "therapeutic", "traditional medicine", "apoptosis", "pyroptosis", autophagy", " Results: Forty-two drugs in the TPM have been chosen in this review. The plant extract, Chinese herbal compound, and pure compound of TPM exhibit significant anticancer activity against PCa by regulating multiple kinds of PCD. More importantly, PI3K/AKT/mTOR, AMPK/mTOR pathways, AKT1/Bcl2/NF-κB, GPBAR1/NF-κB, Keap1/Nrf2/ARE, PINK1/Parkin signaling pathways serve as critical molecular targets mediating the anticancer activities of TPMs in PCD. Autophagy, apoptosis, and ferroptosis are research hotspots, while pyroptosis and necroptosis are less explored. Apoptosis is co-detected with autophagy, or necroptosis. Ferroptosis is co-detected with necroptosis, or pyroptosis. Notably, the interrelationships between these cell death modes are rarely investigated in depth in the treatment of TPM in PCa. TPM has been induced apoptosis, ferroptosis, necroptosis in PCa. But the effect of TPM on the autophagy and pyroptosis need further evidence to clarify the mechanism. Conclusion: Hence, it is imperative to focus on elucidating the role of PCD modulators to refine therapeutic strategies of TPM in PCa.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.